| Name | Title | Contact Details |
|---|
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.
Novel therapeutics for metabolic and endocrine disorders
Cellular Engineering Technologies is a Iowa City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.